acetylcysteine for the treatment of cannabis dependence: working mechanisms

niversity Hospital Brussels (UZ Brussel)0 个研究点开始时间: 2016年1月18日最近更新: 2016年8月8日

适应症

试验速览

暂无简介。

•Males, aged 18-45 years;
•Current DSM-IV diagnosis of cannabis dependence, >1 week detoxified and abstinent;
•Able to provide written informed consent and to comply with study procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Currently dependent on any substance other than cannabis, alcohol or nicotine;
•History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease);
•An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;
•An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;
•Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants);
•Exclusion criteria for MRI: having metal in the body and/or having claustrophobia

发起方

niversity Hospital Brussels (UZ Brussel)